Lummy(SZ:300006)2022-04-26 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥198,706,756.18, a decrease of 44.85% compared to ¥360,285,615.95 in the same period last year[2]. - The net profit attributable to shareholders was a loss of ¥26,403,512.18, representing a decline of 153.99% from a profit of ¥48,906,334.40 in the previous year[2]. - Total operating revenue for Q1 2022 was ¥198.71 million, a decrease of 44.83% compared to ¥360.29 million in Q1 2021[20]. - Net profit for Q1 2022 was a loss of ¥28.99 million, compared to a profit of ¥51.99 million in Q1 2021, representing a significant decline[22]. - The company's weighted average return on equity was -1.23%, down from 3.89% in the same period last year, reflecting a decline in profitability[2]. Cash Flow - The net cash flow from operating activities was negative at ¥12,698,605.55, a decrease of 217.99% compared to a positive cash flow of ¥10,762,664.57 in the same period last year[9]. - Cash inflow from operating activities totaled CNY 361,719,605.84, down from CNY 468,681,207.39 in the previous period, representing a decrease of approximately 22.8%[25]. - The company reported a decrease in cash received from the sale of goods and services, totaling CNY 259,387,820.99, down from CNY 393,068,914.79[25]. - The company incurred a cash outflow of CNY 216,910,988.29 for other operating activities, compared to CNY 278,470,838.39 in the previous period[26]. - The net cash flow from financing activities was ¥138,911,533.03, a decrease of 76.55% compared to ¥592,326,334.50 in the same period last year, primarily due to reduced fundraising activities[9]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,008,325,816.56, an increase of 2.79% from ¥2,926,773,933.76 at the end of the previous year[2]. - Total liabilities for Q1 2022 were ¥825.86 million, up from ¥714.65 million in Q1 2021, indicating a rise of 15.59%[19]. - The total equity attributable to shareholders of the parent company was ¥2.13 billion, down from ¥2.16 billion in the previous year[19]. - The company reported cash and cash equivalents of ¥655,776,074.87 at the end of the period, an increase from ¥559,430,726.55 at the beginning of the year[16]. Investments and Expenses - Research and development expenses increased by 188.19% to ¥24,046,667.47, up from ¥8,344,155.61 in the previous year, indicating a significant investment in new product development[7]. - The company incurred a credit impairment loss of ¥10,287,885.81, which was not applicable in the previous year, indicating an increase in bad debt provisions[8]. - Long-term equity investments increased by 41.45% to ¥132,576,418.45, attributed to increased external investments during the reporting period[7]. - The company reported a significant increase in accounts payable, which rose to ¥37.47 million from ¥34.26 million, an increase of 6.45%[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,942[10]. - The largest shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., holds 23.43% of shares, totaling 247,426,064 shares[10]. - The second-largest shareholder, Qiu Yu, holds 13.27% of shares, totaling 140,080,000 shares, which are currently frozen[10]. - The company has a total of 211,111,111 shares held under lock-up conditions by the largest shareholder[10]. - The company has a total of 21,447,778 shares held by the investment fund, accounting for 2.03% of total shares[10]. Legal and Regulatory Matters - A court case involving the company and Changchun Haiyue Pharmaceutical Co., Ltd. has resulted in the freezing of some bank account funds[14]. - The company attempted to auction 11,380,000 shares held by Qiu Yu, representing 1.08% of total shares, but the auction was unsuccessful[15]. - The company received approval for the injection of methylprednisolone sodium succinate (40mg) after passing the consistency evaluation for generic drug quality and efficacy[14]. Audit and Reporting - The company did not conduct an audit for the first quarter report[27].